The Osteosarcoma Biobank in Peking University People's Hospital
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03362086|
Recruitment Status : Not yet recruiting
First Posted : December 5, 2017
Last Update Posted : December 5, 2017
|Condition or disease|
Samples of blood and other stored material such as slides,frozen tissues and so on .
Questionnaire information, including health history, growth and development, physical activity and family medical history information.
|Study Type :||Observational|
|Estimated Enrollment :||180 participants|
|Official Title:||Establishment of Osteosarcoma Biobank|
|Estimated Study Start Date :||February 1, 2018|
|Estimated Primary Completion Date :||February 1, 2021|
|Estimated Study Completion Date :||February 1, 2024|
- Examine VEGFR-2 and PD-L1 gene expression osteosarcoma [ Time Frame: 3 years ]To examine the VEGFR2 and programmed cell death ligand 1 (PD-L1) genes expression of the patients with osteosarcoma.And Analyze their differences.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362086
|Contact: Kuisheng Liu, phDemail@example.com|
|Principal Investigator:||Tingting Ren, phD||Peking University People's Hospital|